EVE HEALTH GROUP ORD
EVE Health Signs Telehealth Agreement with hubMed to Support Dyspro and Libbo Launches
EVE Health Group (ASX: EVE) has entered into a telehealth services agreement with hubMed to enhance the quality and continuity of care for patients using EVE’s therapeutic products including Dyspro for dysmenorrhoea and Libbo for erectile dysfunction.
EVE Health Appoints Medical Science Liaison to Drive Clinical Engagement
EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.
EVE Health Enters Commercial Rollout Phase for Dyspro and Libbo Following First Prescriptions and Purchase Orders
EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an oral dissolving film for erectile dysfunction.
EVE Health Secures $1.1m Funding to Propel Dyspro and Libbo Product Launches
EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement attracted bids in excess of the $1 million EVE initially sought, the company increased the offer to $1.1m, the maximum capacity […]
